{"d":{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')","uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')","type":"itsystems.Pd.DataServices.DataModel.Business"},"BusinessResponsibilities":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/BusinessResponsibilities"}},"RelatedBusinesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/RelatedBusinesses"}},"BusinessRoles":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/BusinessRoles"}},"Publications":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/Publications"}},"LegislativePeriods":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/LegislativePeriods"}},"Sessions":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/Sessions"}},"Preconsultations":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/Preconsultations"}},"Bills":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/Bills"}},"Councils":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/Councils"}},"BusinessTypes":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/BusinessTypes"}},"Votes":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/Votes"}},"SubjectsBusiness":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/SubjectsBusiness"}},"BusinessStates":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/BusinessStates"}},"Council":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/Council"}},"Transcripts":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20094009,Language='FR')/Transcripts"}},"ID":20094009,"Language":"FR","BusinessShortNumber":"09.4009","BusinessType":6,"BusinessTypeName":"Postulat","BusinessTypeAbbreviation":"Po.","Title":"Autorisation des m\u00e9dicaments et des vaccins","Description":null,"InitialSituation":null,"Proceedings":null,"DraftText":null,"SubmittedText":"

Je charge le Conseil f\u00e9d\u00e9ral de traiter rapidement et prioritairement la question de la coop\u00e9ration avec l'UE dans le domaine des m\u00e9dicaments, en vue de collaborer plus \u00e9troitement avec l'Agence europ\u00e9enne pour l'\u00e9valuation des m\u00e9dicaments. Il fera rapport au Parlement sur les points suivants\u00a0:

a. \u00e9laboration d'un accord sur l'\u00e9change automatique d'informations dans le domaine des m\u00e9dicaments, portant \u00e9galement sur l'\u00e9change de donn\u00e9es confidentielles, sur le mod\u00e8le des accords d\u00e9j\u00e0 conclus avec les \u00c9tats-Unis, le Canada, l'Australie et Singapour, et pr\u00e9sentation d'un calendrier pour la conclusion d'un tel accord\u00a0;

b. autres moyens concrets de renforcer et simplifier la collaboration dans le domaine des m\u00e9dicaments et pr\u00e9sentation d'un calendrier pour la conclusion de tels accords\u00a0;

c. conditions et possibilit\u00e9s de mise en place d'une collaboration plus pouss\u00e9e avec l'UE pour l'autorisation des m\u00e9dicaments et des vaccins\u00a0;

d. avantages et inconv\u00e9nients d'une reprise imm\u00e9diate de la l\u00e9gislation de l'UE dans le domaine des m\u00e9dicaments.

","ReasonText":"

Malgr\u00e9 la d\u00e9finition d'un plan de lutte contre la pand\u00e9mie de grippe porcine et malgr\u00e9 un d\u00e9lai consid\u00e9rable pour s'y pr\u00e9parer, les autorit\u00e9s ont rencontr\u00e9 des difficult\u00e9s qui ont inqui\u00e9t\u00e9 la population. Pour y rem\u00e9dier, il faut am\u00e9liorer notamment notre proc\u00e9dure d'autorisation des m\u00e9dicaments et notre collaboration internationale. Le Conseil f\u00e9d\u00e9ral a d\u00e9j\u00e0 propos\u00e9 d'adopter la motion Maury Pasquier 09.3208, qui vise \u00e0 faciliter l'acc\u00e8s aux m\u00e9dicaments reconnus. Les dispositions d'ex\u00e9cution de l'article 13 de la loi sur les produits th\u00e9rapeutiques (RS 812.21) devraient donc bient\u00f4t \u00eatre modifi\u00e9es en cons\u00e9quence. Ces modifications ne r\u00e9gleront toutefois pas les probl\u00e8mes pos\u00e9s notamment par les pand\u00e9mies, \u00e0 savoir le d\u00e9p\u00f4t parall\u00e8le de demandes d'autorisation.

","DocumentationText":null,"MotionText":null,"FederalCouncilResponseText":"Le Conseil f\u00e9d\u00e9ral propose d'accepter le postulat.","FederalCouncilProposal":18,"FederalCouncilProposalText":"Le Conseil f\u00e9d\u00e9ral propose d'accepter le postulat.","FederalCouncilProposalDate":"\/Date(1264550400000)\/","SubmittedBy":"Heim Bea","BusinessStatus":229,"BusinessStatusText":"Liquid\u00e9","BusinessStatusDate":"\/Date(1465257600000)\/","ResponsibleDepartment":4,"ResponsibleDepartmentName":"D\u00e9partement de l'int\u00e9rieur","ResponsibleDepartmentAbbreviation":"DFI","IsLeadingDepartment":true,"Tags":"2841","Category":null,"Modified":"\/Date(1750809805983)\/","SubmissionDate":"\/Date(1259107200000)\/","SubmissionCouncil":1,"SubmissionCouncilName":"Conseil national","SubmissionCouncilAbbreviation":"CN","SubmissionSession":4812,"SubmissionLegislativePeriod":48,"FirstCouncil1":1,"FirstCouncil1Name":"Conseil national","FirstCouncil1Abbreviation":"CN","FirstCouncil2":null,"FirstCouncil2Name":null,"FirstCouncil2Abbreviation":null,"TagNames":"Sant\u00e9"}}